MEDICATION UTILIZATION AND STATIN ADHERENCE IN THE MANAGEMENT OF DYSLIPIDEMIA AT THONG NHAT HOSPITAL, HO CHI MINH CITY, 2016-2023

Nguyễn Thanh Huy 1 , Lê Hoàng Minh Tâm 1 , Trần Ngọc Thiên Phú 1 , Quang Ánh Nguyệt 1 , Phạm Thị Thu Hiền 2 , Phạm Đình Luyến 1 ,
1 University of Medicine and Pharmacy at Ho Chi Minh City image/svg+xml
2 Thong Nhat Hospital image/svg+xml
* Corresponding author:

Article Information

Metrics
Downloads: 13 Views: 30
DOI
10.63947/bvtn.v2i6.12
Published
2026-02-27
Issue Vol. 2 No. 6 (2026): Thách thức trong lão khoa 2026: Những giải pháp điều trị và chăm sóc toàn diện
Section
Original Research

Download Article

PDF (Vietnamese)

How to Cite

1.
Huy NT, Tâm LHM, Phú TNT, Nguyệt Q Ánh, Hiền PTT, Luyến P Đình. MEDICATION UTILIZATION AND STATIN ADHERENCE IN THE MANAGEMENT OF DYSLIPIDEMIA AT THONG NHAT HOSPITAL, HO CHI MINH CITY, 2016-2023. JHA [Internet]. Vietnam; 2026 Feb. 27 [cited 2026 Mar. 15];2(6). https://tcsuckhoelaohoa.vn/bvtn/article/view/162 doi: 10.63947/bvtn.v2i6.12
Loading citation...
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Dyslipidemia (DLP) is a major risk factor for cardiovascular disease, and statins are the first-line treatment. The level of adherence to statin treatment has a significant impact on treatment outcomes in patients. This study aims to evaluate the medication utilization patterns and statin adherence levels at Thong Nhat Hospital during the 2016-2023 period. A retrospective cross-sectional study was conducted on 23,373 outpatients with dyslipidemia (ICD-10: E78) who had a continuous treatment duration of ≥1 year. Demographic characteristics, comorbidities (CCI), and prescription information were analyzed; statin adherence levels were assessed using MPR and PDC, with the threshold for good adherence being MPR >80% và PDC ≥80%. The mean age was 66,1 ± 12,2 with 72% of patients aged ≥ 60 years and a high multimorbidity burden (mean CCI of 5.91). Among 461,435 examination visits with prescribed treatment, statins accounted for 96.4%, primarily rosuvastatin and atorvastatin at moderate doses. The utilization rate of fixed-dose combinations (FDC) increased from 10.1% (2016) to 25.5% (2023). Adherence levels were low, with a mean MPR of 0.33 and PDC of 0.30; only 5.64% of patients achieved MPR > 80% and 3.53% achieved PDC ≥80%. The study indicates that statins are primarily used in dyslipidemia treatment with a growing trend toward FDC usage; however, the level of treatment adherence remains low.

Keywords

dyslipidemia statin treatment adherence MPR PDC

References

  1. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews. 2019 Apr 1;40(2):537-557. doi:10.1210/er.2018-00184. DOI: https://doi.org/10.1210/er.2018-00184
  2. Bộ Y tế. Báo động thực trạng thừa cholesterol: Hệ lụy và giải pháp. Tin tổng hợp - Cổng thông tin Bộ Y tế. Published 2022. Accessed December 25, 2024. https://moh.gov.vn/tin-tong-hop/-/asset_publisher/k206Q9qkZOqn/content/bao-ong-thuc-trang-thua-cholesterol-he-luy-va-giai-phap.
  3. Dung PT, Hung NT, van Vuong D, et al. Prevalence of dyslipidemia and associated factors among adults in rural Vietnam. Systematic Reviews in Pharmacy. 2020;11(1).
  4. Jones LK, East C, Ganda OP, Gionfriddo MR. Adherence to Lipid-Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2025 Jan;14(1). doi:10.1161/JAHA.124.037530. DOI: https://doi.org/10.1161/JAHA.124.037530
  5. Kardas P, Kwiatek A, Włodarczyk P, Urbański F, Ciabiada-Bryła B. Statins use amidst the pandemic: prescribing, dispensing, adherence, persistence, and correlation with COVID-19 statistics in nationwide real-world data from Poland. Frontiers in Pharmacology. 2024 Apr 9;15:1350717. doi:10.3389/fphar.2024.1350717. DOI: https://doi.org/10.3389/fphar.2024.1350717
  6. Trần Thị Kim Hoa,, Nguyễn Thắng, Nguyễn Sơn Nam, Trần Quốc Tường. NGHIÊN CỨU SỰ TUÂN THỦ DÙNG THUỐC STATIN VÀ KIỂM SOÁT LDL-C Ở BỆNH NHÂN ĐIỀU TRỊ NGOẠI TRÚ TẠI BỆNH VIỆN ĐA KHOA TRUNG TÂM AN GIANG NĂM 2022-2023. Tạp chí Y học Việt Nam. 2023;529(2). doi:10.51298/vmj.v529i2.6526. DOI: https://doi.org/10.51298/vmj.v529i2.6526
  7. Thái T Dịu, Nguyễn T Mai. Tuân thủ dùng thuốc Statin và kiểm soát LDL-C điều trị rối loạn lipid máu tại Bệnh viện Đa khoa Thống Nhất tỉnh Đồng Nai. Tạp chí Khoa học Trường Đại học Quốc tế Hồng Bàng. 2024 Nov;32:109-116. doi:10.59294/HIUJS.2024.703. DOI: https://doi.org/10.59294/HIUJS.32.2024.703
  8. Hoàng TM Nguyệt, Hoàng TQ Nhi, Đào TC Minh, Trần PM Đăng, Nguyễn TN Thảo, La B Ngọc. Nghiên cứu sự tuân thủ sử dụng thuốc và kiểm soát LDL-C ở bệnh nhân rối loạn lipid máu có sử dụng statin tại Bệnh viện Trung ương Huế. TNU Journal of Science and Technology. 2024;230(01):368-375. doi:10.34238/tnu-jst.11018. DOI: https://doi.org/10.34238/tnu-jst.11018
  9. Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the Medication Possession Ratio. Patient Prefer Adherence. 2017;11:1469-1478. doi:10.2147/PPA.S136890. DOI: https://doi.org/10.2147/PPA.S136890
  10. Pharmacy Quality Alliance. Adherence Measures. Published 2022. Accessed January 3, 2025. https://www.pqaalliance.org/adherence-measures.
  11. Dang AK, Thi Le LT, Pham NM, et al. An upward trend of dyslipidemia among adult population in Vietnam: Evidence from a systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2025. DOI: https://doi.org/10.1016/j.dsx.2024.103171
  12. Van Nguyen S, Nguyen DH, Van Dang V, et al. Assessing LDL Cholesterol Management and Statin Use in Diabetic Patients: Disparities and Outcomes in a Vietnamese Tertiary Hospital Setting. Biomedical Research and Therapy. 2024;11(4). DOI: https://doi.org/10.15419/bmrat.v11i4.876
  13. Guadamuz JS, Shooshtari A, Qato DM. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015-2020. BMJ Open. 2022;12(9). DOI: https://doi.org/10.1136/bmjopen-2022-061350
  14. Belančić A, Štiglić MK, Prgomet L, et al. Trends in Lipid-Lowering Agent Consumption in Croatia: A 25-Year Observational Study. Pharmacol Res Perspect. 2025;13(3). DOI: https://doi.org/10.1002/prp2.70122
  15. Llanes EJB, Thongtang N, Lee ZV, et al. Addressing adherence challenges in long-term statin treatment among Asian populations: Current gaps and proposed solutions. Am J Prev Cardiol. 2025. DOI: https://doi.org/10.1016/j.ajpc.2025.101019

License

© 2026 The Author(s). Published by Journal of Health and Aging.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.